Close Menu

NEW YORK (GenomeWeb) — Co-Diagnostics announced today that it has sold $3 million worth of preferred stock in a transaction that eliminates the Salt Lake City, Utah-based company's debt.

According to Co-Diagnostics, the preferred shares are convertible into common stock at a price of $1.20 per share. The deal included negotiating the conversion of a $2 million note to preferred stock, as well as the sale of an additional $1 million of preferred stock for cash.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.


Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Sponsored by

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 


This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.